https://www.selleckchem.com/products/ficz.html
4 value than fulvestrant. And further molecular docking study revealed that compound XH04 possessed a proverbial and typical binding model with ERα like other reported SERD. All these results confirmed that 7-hydroxy-2H-chromene-3-carbonyl structure could be a feasible skeleton for design of ERα antagonists including SERDs and compound XH04 is a promising candidate for further development of ERα + breast cancer therapy agents.Breast cancer (BC) is one of the most common malignances and is a leading cause of cancer-related deaths in women g
Me gusta
Comentario
Compartir
